Date: 2015-11-03
Type of information: IPO
Company: Mesoblast (Australia)
Investors:
Amount:
Funding type:
Planned used: Mesoblast intends to use the net proceeds of this offering for ongoing clinical programs, research and development expenses, commercial manufacturing requirements, and general and administrative purposes.
Others: * On November 3, 2015, Mesoblast announced that it has filed a US registration statement on Form F-1 with the U.S. Securities and Exchange Commission, offering 5,742,510 American Depositary Shares (ADSs) in the United States, with each ADS representing five fully paid ordinary shares of Mesoblast. The actual number of ADSs and the issue price, in U.S. dollars, will be determined by Mesoblast in conjunction with the Company’s underwriters at the conclusion of the offer process. * On October 30, 2015, Mesoblast announced that it plans to conduct a registered initial public offering in the United States. Mesoblast has previously submitted to the U.S. Securities and Exchange Commission (the “SEC”) a draft registration statement. Mesoblast intends to publicly file its registration statement with the SEC and commence the offering next week. This announcement is being made pursuant to and in accordance with Rule 135 under the U.S. Securities Act of 1933.
Mesoblast has applied to list its ADSs on the Nasdaq Global Select Market under the symbol “MESO”, where they will trade in U.S. dollars. Mesoblast’s Shares will continue to trade on the ASX in Australian dollars. JP Morgan and Credit Suisse are acting as joint bookrunning managers of the offering and the representatives of the underwriters.
Therapeutic area:
